Feature | March 24, 2014

New Treatment for Atrial Fibrillation Reduces Stroke Risk

Lariat device seals the left atrial appendage

atrial fibrillation, LARIAT

March 24, 2014 – Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation (AF) who cannot tolerate blood-thinning medication.
 
AF is the most common heart rhythm disorder that causes the upper chambers of the heart to beat fast and erratically. An estimated 2.7 million Americans are living with the disorder, and if uncontrolled, it can have serious consequences, including stroke and early death. Currently, the condition accounts for more than 20 percent of stroke-related deaths.
 
Patients are normally given blood thinners such as warfarin and other anticoagulants to manage their condition by preventing blood clots. However, patients must rigorously manage the level of the drugs in their blood. For most patients, these blood thinners are very effective in reducing the risk of stroke, but there is a potential for bleeding, which in some cases can be serious. For those individuals who cannot tolerate blood thinners due to prior bleeding or who are at a high risk for bleeding, the Lariat procedure can safely reduce the risk of stroke without any further bleeding risk.
 
The Lariat procedure is a nonsurgical, minimally-invasive technique that uses sutures to tie off the left atrial appendage (LAA) of the heart. This area of the heart is the primary source of blood clots leading to stroke in patients with atrial fibrillation.
 
With the patient under general anesthesia, physicians guide two catheters into the patient’s heart to seal the LAA with a pre-tied suture loop — similar to a lasso — with the Lariat device. Rather than a surgical procedure, the technique uses a needle to introduce catheters into the heart.
 
“In the past there weren’t any alternatives that we could really offer these types of patients,” said Roger Fan, M.D., associate professor, department of medicine, director of arrhythmia consult service. “The Lariat is a great alternative to the possibility of a lifetime of blood thinners, which can have some serious side effects like GI bleeds, as well as an alternative to invasive open-heart surgery.” 
 
On Dec. 3, 2013, Fan and his team at the Stony Brook Heart Institute completed their first Lariat procedure without having to spread the ribcage or cut through bone to reach the heart.
 
For more information, visit www.heart.stonybrookmedicine.edu

Related Content

News | Left Atrial Appendage (LAA) Occluders

April 4, 2024 — Osso VR, a leader in immersive procedural training, announces the release of a co-developed curriculum ...

Home April 04, 2024
Home
News | Left Atrial Appendage (LAA) Occluders

March 18, 2024 — Conformal Medical, Inc. announced that the CLAAS System was featured in a podium presentation at the ...

Home March 18, 2024
Home
News | Left Atrial Appendage (LAA) Occluders

January 8, 2024 — University Hospitals (UH) Harrington Heart & Vascular Institute recently became the first center in ...

Home January 08, 2024
Home
News | Left Atrial Appendage (LAA) Occluders

October 25, 2023 — ConcertAI's TeraRecon, a leader in advanced visualization and artificial intelligence (AI) for ...

Home October 25, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

October 25, 2023 — Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing ...

Home October 25, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

October 19, 2023 — Conformal Medical, Inc. announced today the one-year results from the company's CONFORMAL Early ...

Home October 19, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

September 7, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval ...

Home September 07, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

July 26, 2023 — Abbott is recalling the Amplatzer Steerable Delivery Sheath due to an increased risk for air emboli to ...

Home July 26, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

May 25, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 25, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

May 22, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 22, 2023
Home
Subscribe Now